A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
=== Dogs === Hyperthyroidism is much less common in dogs compared to cats. Hyperthyroidism may be caused by a thyroid tumor. This may be a thyroid carcinoma. About 90% of carcinomas are very aggressive; they invade the surrounding tissues and metastasize (spread) to other tissues, particularly the lungs. This has a poor prognosis. Surgery to remove the tumor is often very difficult due to metastasis into arteries, the esophagus, or the windpipe. It may be possible to reduce the size of the tumor, thus relieving symptoms and allowing time for other treatments to work. About 10% of thyroid tumors are benign; these often cause few symptoms. In dogs treated for hypothyroidism (lack of thyroid hormone), iatrogenic hyperthyroidism may occur as a result of an overdose of the thyroid hormone replacement medication, levothyroxine; in this case, treatment involves reducing the dose of levothyroxine. Dogs which display coprophagy, the consumption of feces, and also live in a household with a dog receiving levothyroxine treatment, may develop hyperthyroidism if they frequently eat the feces from the dog receiving levothyroxine treatment. Hyperthyroidism may occur if a dog eats an excessive amount of thyroid gland tissue. This has occurred in dogs fed commercial dog food.
=== Iodine === Iodine is used in chemistry as an indicator for starch. When starch is mixed with iodine in solution, an intensely dark blue colour develops, representing a starch/iodine complex. Starch is a substance common to most plant cells and so a weak iodine solution will stain starch present in the cells. Iodine is one component in the staining technique known as Gram staining, used in microbiology. Used as a mordant in Gram's staining, iodine enhances the entrance of the dye through the pores present in the cell wall/membrane. Lugol's solution or Lugol's iodine (IKI) is a brown solution that turns black in the presence of starches and can be used as a cell stain, making the cell nuclei more visible. Used with common vinegar (acetic acid), Lugol's solution is used to identify pre-cancerous and cancerous changes in cervical and vaginal tissues during "Pap smear" follow up examinations in preparation for biopsy. The acetic acid causes the abnormal cells to blanch white, while the normal tissues stain a mahogany brown from the iodine.
A positive diagnosis test for thiamine deficiency involves measuring the activity of the enzyme transketolase in erythrocytes (erythrocyte transketolase activation assay). Alternatively, thiamine and its phosphorylated derivatives can directly be detected in whole blood, tissues, foods, animal feed, and pharmaceutical preparations following the conversion of thiamine to fluorescent thiochrome derivatives (thiochrome assay) and separation by high-performance liquid chromatography. Capillary electrophoresis techniques and in-capillary enzyme reaction methods have emerged as alternative techniques in quantifying and monitoring thiamine levels in samples. The normal thiamine concentration in EDTA-blood is about 20–100 μg/L.
Loeb (1983), billionaire, hedge fund manager, founder of Third Point Management Kai-Fu Lee (1983), Taiwanese IT Venture Capitalist, founder of Google China and Microsoft Research Asia Steve Perlman (1983), founder and CEO of Artemis Networks; inventor of QuickTime, MSN TV, pCell, and Mova Contour facial motion capture technology Jonathan Abbott (1984), president and CEO of WGBH Educational Foundation Randy Lerner (1984), billionaire, ex-owner of Cleveland Browns and Aston Villa F.C., son of billionaire Alfred Lerner '55 James Satloff (1984), founder of Liberty Skis and former president and CEO of C.E.
A chronic wound is a wound that does not progress through the normal stages of wound healing—hemostasis, inflammation, proliferation, and remodeling—in a predictable and timely manner. Typically, wounds that do not heal within three months are classified as chronic. Chronic wounds may remain in the inflammatory phase due to factors like infection or bacterial burden, ischaemia, presence of necrotic tissue, improper moisture balance of wound site, or underlying diseases such as diabetes mellitus. In acute wounds, a regulated balance of pro-inflammatory cytokines (signalling molecules) and proteases (enzymes) prevent the degradation of the extracellular matrix (ECM) and collagen to ensure proper wound healing. In chronic wounds, there is excessive levels of inflammatory cytokines and proteases, leading to excessive degradation of the ECM and collagen. This disrupts tissue repair and impedes recovery, keeping the wound in a non-healing state. Chronic wounds may take years to heal or, in some cases, may never heal, causing significant physical and emotional stress for patients and placing a financial burden on healthcare systems. Acute and chronic wounds are part of a spectrum, with chronic wounds requiring prolonged and complex care compared to acute wounds.
Sources: en.wikipedia.org
== Production == In January 1995, it was reported that 20th Century Fox had secured deals with Keanu Reeves and Andrew Davis to star in and direct respectively the action thriller Dead Drop. Reeves was reportedly paid $7 million upfront against at least 5% of first-dollar gross for his role while Davis was reportedly paid $5 million. Large portions of the film were shot on location in and around Chicago, Illinois, including the University of Chicago, Argonne National Laboratory, the Museum of Science and Industry, the Field Museum of Natural History, Michigan Avenue, and the James R. Thompson Center (Atrium Mall). Additional scenes were shot at Yerkes Observatory in Williams Bay, Wisconsin, on Geneva Lake in southern Wisconsin, interiors of the U.S. Capitol were shot at the Wisconsin State Capitol, in Madison, Wisconsin, at Inland Steel Company (now known as Cleveland-Cliffs Inc.) in East Chicago, Indiana, and at a private residence in Barrington Hills, Illinois. Because of the cold Great Lakes winter and filming taking place during record-breaking winter weather, unique challenges were present for the cast and crew. Morgan Freeman noted "It was difficult for everyone, particularly for me because I'm tropical," he said. "I don't do cold weather. This is Chicago...in the winter. I was ill and in bed [for] four days at a crack. It was really rough."
DiCaprio is agnostic. His personal life is the subject of widespread media attention, though he rarely grants interviews and is reluctant to discuss his private life. Since his 40s, DiCaprio has been the focus of various reports detailing his involvement with women aged 25 or younger, and has faced criticism for the age disparity of those relationships. In 1999, DiCaprio met Brazilian model Gisele Bündchen, whom he dated until 2005. He was romantically involved with Israeli model Bar Refaeli from 2005 to 2011. He later dated German fashion model Toni Garrn from 2013 to 2014 and later in 2017. DiCaprio was briefly romantically linked with Barbadian singer Rihanna, with the pair attending Coachella together in 2016. DiCaprio successfully sued French tabloid Oops after it made claims that DiCaprio had gotten Rihanna pregnant. DiCaprio was in a relationship with American model and actress Camila Morrone from 2017 until 2022. He has been dating Italian model Vittoria Ceretti since August 2023. DiCaprio owns houses in Los Angeles and apartments in New York City. In 2009, he bought an island, Blackadore Caye, off mainland Belize—on which he is set to open an environmentally friendly resort—and in 2014, he purchased the original Dinah Shore residence designed by architect Donald Wexler in Palm Springs, California. In 2005, DiCaprio's face was severely injured when model Aretha Wilson hit him over the head with a broken bottle at a Hollywood party. As a result, he required seventeen stitches to his face and neck.
== Services == Allergy and Asthma Arthritis and Rheumatology Bariatrics Behavioral Health Cancer Children's Dermatology Ear, Nose and Throat Emergency and Trauma Employee Health and Wellness Endocrinology Family Medicine and Primary Care Gastroenterology Geriatrics Heart and Vascular Home Health Hospice Immediate and Walk-In Care Nephrology Neurology and Neurosurgery Ophthalmology Orthopedics and Sports Medicine Pain Management Palliative Care Physical Medicine and Rehabilitation Pulmonology and Respiratory Radiology Sleep Surgery Therapy and Rehabilitation Transplant Urology Wellness and Prevention Women's Wound
NMNAT enzymatic activity is probably essential at the cellular level, as complete ablation of NMNAT activity in model organisms leads to cellular inviability. NMNAT1 enhancement opposes the actions of SARM1 which would lead to axon degeneration, but this effect is not due to preventing SARM1 depletion of NAD+.
During 1990, in the capital city of Mogadishu, the residents were prohibited from gathering publicly in groups greater than three or four. Fuel shortages, inflation, and currency devaluation impacted the economy. A thriving black market existed in the centre of the city as banks experienced shortages of local currency for exchange. Harsh exchange control regulations were introduced to prevent export of foreign currency. Although no travel restrictions were placed on foreigners, photographing many locations was banned. During daytime in Mogadishu, the appearance of any government military force was extremely rare. Alleged late-night operations by government authorities, however, included "disappearances" of individuals from their homes. In 1991, the Barre administration was ousted by a coalition of clan-based opposition groups, backed by Ethiopia's then-ruling Derg regime and Libya. Following a meeting of the Somali National Movement and northern clans' elders, the northern former British portion of the country declared its independence as the Republic of Somaliland in May 1991. Although de facto independent and relatively stable compared to the tumultuous south, it was not recognised by any foreign government, until Israel recognised it in 2025.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.